Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors
Tsimberidou, Apostolia M, Beer, Philip A, Cartwright, Carrie A, Haymaker, Cara, Vo, Henry H, Kiany, Simin, Cecil, Alexander R L, Dow, James, Haque, Kemal, Silva, Franck A, Coe, Lucy, Berryman, Helen, Bone, Elisabeth A, Nogueras-Gonzalez, Graciela M, Vining, David, McElwaine-Johnn, Hilary, Wistuba, Ignacio I
Published in Clinical cancer research (01.07.2021)
Published in Clinical cancer research (01.07.2021)
Get full text
Journal Article
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma
Nastoupil, Loretta J., Neelapu, Sattva S., Davis, Richard Eric, Samaniego, Felipe, Fowler, Nathan H., Westin, Jason, Lee, Hun Ju, Wang, Michael, Hagemeister, Fredrick, Cecil, Alexander R. L., Dow, James, Haque, Kemal, Silva, Franck A., Whale, Andrew, Lensun, Letitia, Bone, Elisabeth A., McElwaine-Johnn, Hilary, Beer, Philip A.
Published in Leukemia & lymphoma (06.12.2021)
Published in Leukemia & lymphoma (06.12.2021)
Get full text
Journal Article